MediPharm Labs Gestion

Gestion contrôle des critères 3/4

Le PDG MediPharm Labs est David Pidduck, nommé en Apr2022, a un mandat de 2.58 ans. La rémunération annuelle totale est CA$ 1.31M, composée du salaire de 36% et des bonus 64%, y compris les actions et options de la société. détient directement 4.08% des actions de la société, d'une valeur de € 735.25K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 5.1 ans et 5.4 ans.

Informations clés

David Pidduck

Directeur général

CA$1.3m

Rémunération totale

Pourcentage du salaire du PDG	36.0%
Durée du mandat du directeur général	2.6yrs
Propriété du PDG	4.1%
Durée moyenne d'occupation des postes de direction	5.1yrs
Durée moyenne du mandat des membres du conseil d'administration	5.4yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de David Pidduck a-t-elle évolué par rapport aux bénéfices de MediPharm Labs?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-CA$12m
Jun 30 2024	n/a	n/a	-CA$13m
Mar 31 2024	n/a	n/a	-CA$14m
Dec 31 2023	CA$1m	CA$470k	-CA$13m
Sep 30 2023	n/a	n/a	-CA$16m
Jun 30 2023	n/a	n/a	-CA$20m
Mar 31 2023	n/a	n/a	-CA$26m
Dec 31 2022	CA$3m	CA$315k	-CA$30m

Rémunération vs marché: La rémunération totale de David ($USD 930.25K ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 476.59K ).

Rémunération et revenus: La rémunération de David a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

David Pidduck

2.6yrs

Titularisation

CA$1,305,051

Compensation

Mr. David A. Pidduck is Chief Executive Officer and Director at MediPharm Labs Corp. since April 20, 2022. Mr. Pidduck has been the Chief Executive Officer and President of Purdue Pharma Inc. since Septemb...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
David Pidduck	CEO & Director	2.6yrs	CA$1.31m	4.08% € 735.3k
Keith Strachan	Co-Founder & President	5.8yrs	CA$819.48k	2.17% € 390.7k
Greg Hunter	Chief Financial Officer	3.8yrs	CA$957.75k	0.31% € 56.6k
Patrick McCutcheon	Founder	9.8yrs	CA$858.16k	pas de données
Brett Moon	Vice President of Sales	4.5yrs	pas de données	pas de données
Kirk Binns	Executive Vice President of Global Accounts	5.8yrs	pas de données	pas de données

5.1yrs

Durée moyenne de l'emploi

Gestion expérimentée: L'équipe dirigeante de MLZ est chevronnée et expérimentée (5.1 années d'ancienneté moyenne).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
David Pidduck	CEO & Director	2.6yrs	CA$1.31m	4.08% € 735.3k
Shelley Martin	Independent Director	4.4yrs	CA$64.49k	0.020% € 3.5k
Michael Bumby	Independent Director	1.6yrs	CA$34.45k	0.050% € 9.0k
Christopher Taves	Independent Chairman of the Board	4.3yrs	CA$87.14k	0.35% € 62.3k
Miriam McDonald	Member of the Science Advisory Board	5.6yrs	CA$32.40k	pas de données
Leslie Brown	Member of the Science Advisory Board	5.6yrs	pas de données	pas de données
Matt Archibald	Member of the Science Advisory Board	5.6yrs	pas de données	pas de données
Markus Roggen	Member of the Science Advisory Board	5.6yrs	pas de données	pas de données
Arshad Hack	Member of the Science Advisory Board	5.6yrs	pas de données	pas de données
Jerry King	Member of the Science Advisory Board	5.6yrs	pas de données	pas de données
Carolina Landolt-Marticorena	Member of the Science Advisory Board	5.3yrs	pas de données	pas de données
Christopher Halyk	Independent Director	4.3yrs	CA$56.05k	0.043% € 7.7k

5.4yrs

Durée moyenne de l'emploi

Conseil d'administration expérimenté: Les membres du conseil d'administration de MLZ sont considérés comme expérimentés (ancienneté moyenne 5.4 ans).

MediPharm Labs Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

MediPharm Labs Corp. Announces Executive Changes

MediPharm Labs Corp., Annual General Meeting, Jun 26, 2024

High number of new and inexperienced directors

Dr. Paul Tam Resigns from the Board of Directors of MediPharm Labs Corp

High number of new and inexperienced directors

MediPharm Labs Corp., Annual General Meeting, Jun 30, 2022

Recent updates

Third quarter 2024 earnings released: CA$0.007 loss per share (vs CA$0.013 loss in 3Q 2023)

MediPharm Labs Corp. to Report Q3, 2024 Results on Nov 14, 2024

MediPharm Labs Corp. Announces Executive Changes

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: CA$0.006 loss per share (vs CA$0.009 loss in 2Q 2023)

MediPharm Labs Corp. to Report Q2, 2024 Results on Aug 14, 2024

MediPharm Labs Corp., Annual General Meeting, Jun 26, 2024

First quarter 2024 earnings released: CA$0.009 loss per share (vs CA$0.01 loss in 1Q 2023)

MediPharm Labs Corp. to Report Q1, 2024 Results on May 15, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings released: CA$0.04 loss per share (vs CA$0.11 loss in FY 2022)

MediPharm Labs Corp. to Report Q4, 2023 Results on Mar 27, 2024

Third quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.03 loss in 3Q 2022)

New minor risk - Profitability

Forecast to breakeven in 2024

MediPharm Labs Corp. to Report Q3, 2023 Results on Nov 14, 2023

Tilray Brands, Inc. (NasdaqGS:TLRY) acquired 1000652011 Ontario Inc. from MediPharm Labs Corp. (TSX:LABS) for CAD 8.5 million.

MediPharm Labs Corp. Settles an Outstanding Claim for $9,000,000 with HEXO Corp

MediPharm Labs Corp. Launches New GMP Products to the Australian Medical Cannabis Market

Medipharm Labs Corp. Publishes Study Investigating Medical Cannabis Impacts on Anxiety and Depression Outcomes in Fibromyalgia Patients

New major risk - Financial position

Second quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.03 loss in 2Q 2022)

MediPharm Labs Corp. to Report Q2, 2023 Results on Aug 14, 2023

MediPharm Labs Corp. Provides Update on US FDA Status

First quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.03 loss in 1Q 2022)

MediPharm Labs Corp. to Report Q1, 2023 Results on May 15, 2023

High number of new and inexperienced directors

MediPharm Labs Corp. (TSX:LABS) entered into a definitive arrangement agreement to acquire VIVO Cannabis Inc. (TSX:VIVO) from directors and officers of VIVO and others for CAD 11.1 million.

Third quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.03 loss in 3Q 2021)

MediPharm Labs Corp. to Report Q3, 2022 Results on Nov 14, 2022

Onelife Botanicals Pty Ltd completed the acquisition of MediPharm Labs Australia Pty Ltd from MediPharm Labs Corp. (TSX:LABS).

Second quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.05 loss in 2Q 2021)

MediPharm Labs Corp. to Report Q2, 2022 Results on Aug 15, 2022

Onelife Botanicals Pty Ltd entered into an agreement to acquire MediPharm Labs Australia Pty Ltd from MediPharm Labs Corp. (TSX:LABS) for AUD 6.9 million.

Dr. Paul Tam Resigns from the Board of Directors of MediPharm Labs Corp

First quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.07 loss in 1Q 2021)

MediPharm Labs Corp. to Report Q1, 2022 Results on May 16, 2022

High number of new and inexperienced directors

MediPharm Labs Corp., Annual General Meeting, Jun 30, 2022

MediPharm Labs Corp. Announces Management Changes

Medipharm Labs Corp Launches CBG and Water-Soluble Products

Full year 2021 earnings released: CA$0.22 loss per share (vs CA$0.48 loss in FY 2020)

MediPharm Labs Corp. to Report Q4, 2021 Results on Mar 31, 2022

MediPharm Labs Corp. to Report Q4, 2021 Results on Mar 31, 2022

Medipharm Labs Enters United States Pharmaceutical Market with Submission of FDA DMF

CEO of Asia Pacific & Director recently sold €60k worth of stock

MediPharm Labs Expands CBN Portfolio with Two New Products

Third quarter 2021 earnings released: CA$0.03 loss per share (vs CA$0.11 loss in 3Q 2020)

Second quarter 2021 earnings released: CA$0.05 loss per share (vs CA$0.02 loss in 2Q 2020)

MediPharm Labs Corp. Receives Canadian GMP Pharmaceutical Drug Establishment Licence

Founder & Chairman of the Board recently sold €329k worth of stock

Independent Director recently bought €206k worth of stock

MediPharm Labs Launches High-CBD Wellness Oils in Quebec

First quarter 2021 earnings released: CA$0.07 loss per share (vs CA$0.13 loss in 1Q 2020)

Full year 2020 earnings released: CA$0.48 loss per share (vs CA$0.014 profit in FY 2019)

MediPharm Labs Expands Distribution Revenue Footprint in Canada, Enters Growing Quebec Market Through New Supply Agreement

Independent Director recently bought €132k worth of stock

Medipharm Labs Corp. Announces Plan to Launch New Over-The-Counter Products

MediPharm Labs Corp. has completed a Composite Units Offering in the amount of CAD 29 million.

Interim Chief Financial Officer has left the company

New 90-day high: €0.57

MediPharm Labs Corp. Appoints Greg Hunter as Chief Financial Officer, Effective February 8, 2021

MediPharm Labs Appoints Warren Everitt to Board of Directors

MediPharm Labs Corp. Enters a Supply Agreement with Nova Scotia Liquor Corporation

New 90-day low: €0.32

MediPharm Labs Corp. Announces Executive Changes

Revenue misses expectations

Third quarter 2020 earnings released: CA$0.11 loss per share

New 90-day low: €0.47